BACKGROUND: When identifying clinical markers predicting clinical outcome, disease recurrence and resistance to therapies often determine the diagnosis and therapy of some cancer types. OBJECTIVE: To investigate whether 14-3-3zeta positive expression is an indicator of prognosis in patients with glioblastoma. METHODS: Forty-seven patients treated with surgery, radiotherapy, and adjuvant chemotherapy between 2005 and 2007 were divided into 2 groups according to 14-3-3zeta expression in an immunohistochemical study: the 14-3-3zeta negative group (n = 12 patients) and the 14-3-3zeta positive group (n = 35 patients). The clinicopathologic features and survival data for patients in the 14-3-3zeta positive group were compared with data from the patients in the 14-3-3zeta negative group. Kaplan-Meier survival analysis and univariate and multivariate analyses were performed to determine the prognostic factors that influenced patient survival. RESULTS: 14-3-3zeta positive expression was observed in approximately 74.5% of patients with glioblastoma. Patients in the 14-3-3zeta positive group had lower overall survival rates and median survival time than those in the 14-3-3zeta negative group (overall 2-year actuarial survival rates, 8.6% for the 14-3-3zeta positive group vs 16.7% for the 14-3-3zeta negative group; overall 2-year median survival time, 12.9 months for the 14-3-3zeta positive group vs 17.9 months for the 14-3-3zeta negative group, P = .019). 14-3-3zeta positive expression in tumor cells also was correlated with a shorter interval to tumor recurrence (median interval to recurrence, 5.9 months in the 14-3-3zeta positive group vs 8.3 months in the 14-3-3zeta negative group, P = .002). Univariate and multivariate analyses showed that 14-3-3zeta positive expression was an independent prognostic factor. CONCLUSION: 14-3-3zeta positive expression can be used as a potential molecular risk factor in patients with glioblastoma.
BACKGROUND: When identifying clinical markers predicting clinical outcome, disease recurrence and resistance to therapies often determine the diagnosis and therapy of some cancer types. OBJECTIVE: To investigate whether 14-3-3zeta positive expression is an indicator of prognosis in patients with glioblastoma. METHODS: Forty-seven patients treated with surgery, radiotherapy, and adjuvant chemotherapy between 2005 and 2007 were divided into 2 groups according to 14-3-3zeta expression in an immunohistochemical study: the 14-3-3zeta negative group (n = 12 patients) and the 14-3-3zeta positive group (n = 35 patients). The clinicopathologic features and survival data for patients in the 14-3-3zeta positive group were compared with data from the patients in the 14-3-3zeta negative group. Kaplan-Meier survival analysis and univariate and multivariate analyses were performed to determine the prognostic factors that influenced patient survival. RESULTS:14-3-3zeta positive expression was observed in approximately 74.5% of patients with glioblastoma. Patients in the 14-3-3zeta positive group had lower overall survival rates and median survival time than those in the 14-3-3zeta negative group (overall 2-year actuarial survival rates, 8.6% for the 14-3-3zeta positive group vs 16.7% for the 14-3-3zeta negative group; overall 2-year median survival time, 12.9 months for the 14-3-3zeta positive group vs 17.9 months for the 14-3-3zeta negative group, P = .019). 14-3-3zeta positive expression in tumor cells also was correlated with a shorter interval to tumor recurrence (median interval to recurrence, 5.9 months in the 14-3-3zeta positive group vs 8.3 months in the 14-3-3zeta negative group, P = .002). Univariate and multivariate analyses showed that 14-3-3zeta positive expression was an independent prognostic factor. CONCLUSION:14-3-3zeta positive expression can be used as a potential molecular risk factor in patients with glioblastoma.
Authors: Sumaiyah K Rehman; Shau-Hsuan Li; Shannon L Wyszomierski; Qingfei Wang; Ping Li; Ozgur Sahin; Yi Xiao; Siyuan Zhang; Yan Xiong; Jun Yang; Hai Wang; Hua Guo; Jitao D Zhang; Daniel Medina; William J Muller; Dihua Yu Journal: Cancer Res Date: 2013-11-06 Impact factor: 12.701
Authors: Yan Xu; Mariateresa Fulciniti; Mehmet K Samur; Matthew Ho; Shuhui Deng; Lanting Liu; Kenneth Wen; Tengteng Yu; Zuzana Chyra; Sanika Dereibal; Li Zhang; Yao Yao; Chandraditya Chakraborty; Eugenio Morelli; Na Li; Michael A Lopez; Tommaso Perini; Shidai Mu; Gang An; Rafael Alonso; Giada Bianchi; Yu-Tzu Tai; Kenneth C Anderson; Lugui Qiu; Nikhil C Munshi Journal: Blood Date: 2020-07-23 Impact factor: 22.113
Authors: Alexandra Surcel; Eric S Schiffhauer; Dustin G Thomas; Qingfeng Zhu; Kathleen T DiNapoli; Maik Herbig; Oliver Otto; Hoku West-Foyle; Angela Jacobi; Martin Kräter; Katarzyna Plak; Jochen Guck; Elizabeth M Jaffee; Pablo A Iglesias; Robert A Anders; Douglas N Robinson Journal: Cancer Res Date: 2019-07-29 Impact factor: 13.312